Oramed Pharmaceuticals Statistics

Total Valuation

TLV:ORMP has a market cap or net worth of ILS 495.24 million. The enterprise value is 97.70 million.

Market Cap	495.24M
Enterprise Value	97.70M

Important Dates

The last earnings date was Thursday, April 2, 2026.

Earnings Date	Apr 2, 2026
Ex-Dividend Date	Jan 16, 2026

Share Statistics

Current Share Class	40.45M
Shares Outstanding	n/a
Shares Change (YoY)	+3.84%
Shares Change (QoQ)	-4.37%
Owned by Insiders (%)	17.49%
Owned by Institutions (%)	20.47%
Float	30.21M

Valuation Ratios

The trailing PE ratio is 2.46.

PE Ratio	2.46
Forward PE	n/a
PS Ratio	77.67
PB Ratio	0.78
P/TBV Ratio	0.78
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	0.48
EV / Sales	16.40
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-3.35

Financial Position

The company has a current ratio of 6.98, with a Debt / Equity ratio of 0.00.

Current Ratio	6.98
Quick Ratio	6.62
Debt / Equity	0.00
Debt / EBITDA	n/a
Debt / FCF	-0.09
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is 37.10% and return on invested capital (ROIC) is -17.91%.

Return on Equity (ROE)	37.10%
Return on Assets (ROA)	-4.88%
Return on Invested Capital (ROIC)	-17.91%
Return on Capital Employed (ROCE)	-7.12%
Weighted Average Cost of Capital (WACC)	11.08%
Revenue Per Employee	1.59M
Profits Per Employee	50.40M
Employee Count	4
Asset Turnover	0.01
Inventory Turnover	n/a

Taxes

In the past 12 months, TLV:ORMP has paid 36.05 million in taxes.

Income Tax	36.05M
Effective Tax Rate	15.01%

Stock Price Statistics

The stock price has increased by +45.64% in the last 52 weeks. The beta is 1.25, so TLV:ORMP's price volatility has been higher than the market average.

Beta (5Y)	1.25
52-Week Price Change	+45.64%
50-Day Moving Average	1,072.83
200-Day Moving Average	893.56
Relative Strength Index (RSI)	66.57
Average Volume (20 Days)	6,012

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	4.14

Income Statement

In the last 12 months, TLV:ORMP had revenue of ILS 6.38 million and earned 201.62 million in profits. Earnings per share was 4.78.

Revenue	6.38M
Gross Profit	41,444
Operating Income	-48.10M
Pretax Income	240.13M
Net Income	201.62M
EBITDA	-47.71M
EBIT	-48.10M
Earnings Per Share (EPS)	4.78

Balance Sheet

The company has 401.35 million in cash and 2.63 million in debt, giving a net cash position of 425.41 million.

Cash & Cash Equivalents	401.35M
Total Debt	2.63M
Net Cash	425.41M
Net Cash Per Share	n/a
Equity (Book Value)	636.78M
Book Value Per Share	16.21
Working Capital	364.02M

Cash Flow

In the last 12 months, operating cash flow was -29.15 million and capital expenditures -28,692, giving a free cash flow of -29.18 million.

Operating Cash Flow	-29.15M
Capital Expenditures	-28,692
Depreciation & Amortization	357,646
Net Borrowing	n/a
Free Cash Flow	-29.18M
FCF Per Share	n/a

Margins

Gross margin is 0.65%, with operating and profit margins of -754.40% and 3,202.50%.

Gross Margin	0.65%
Operating Margin	-754.40%
Pretax Margin	3,766.20%
Profit Margin	3,202.50%
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

This stock pays an annual dividend of 0.79, which amounts to a dividend yield of 6.72%.

Dividend Per Share	0.79
Dividend Yield	6.72%
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-3.84%
Shareholder Yield	2.88%
Earnings Yield	40.71%
FCF Yield	-5.89%

Dividend Details

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

TLV:ORMP has an Altman Z-Score of 1.46 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	1.46
Piotroski F-Score	1